The nuclear factor kappaB inhibitor pyrrolidine dithiocarbamate prevents cardiac remodelling and matrix metalloproteinase-2 up-regulation in renovascular hypertension (2015)
- Authors:
- USP affiliated authors: SANTOS, JOSE EDUARDO TANUS DOS - FMRP ; GERLACH, RAQUEL FERNANDA - FORP
- Unidades: FMRP; FORP
- DOI: 10.1111/bcpt.12400
- Subjects: HIPERTENSÃO; METALOPROTEINASES; RECEPTORES IMUNOLÓGICOS
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2015
- Source:
- Título: Basic and Clinical Pharmacology and Toxicology
- ISSN: 1742-7835
- Volume/Número/Paginação/Ano: v. 117, n. 4, p. 234-241, 2015
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
CAU, Stefany B. A. et al. The nuclear factor kappaB inhibitor pyrrolidine dithiocarbamate prevents cardiac remodelling and matrix metalloproteinase-2 up-regulation in renovascular hypertension. Basic and Clinical Pharmacology and Toxicology, v. 117, n. 4, p. 234-241, 2015Tradução . . Disponível em: https://doi.org/10.1111/bcpt.12400. Acesso em: 26 jan. 2026. -
APA
Cau, S. B. A., Guimarães, D. A., Rizzi, E., Ceron, C. S., Gerlach, R. F., & Tanus-Santos, J. E. (2015). The nuclear factor kappaB inhibitor pyrrolidine dithiocarbamate prevents cardiac remodelling and matrix metalloproteinase-2 up-regulation in renovascular hypertension. Basic and Clinical Pharmacology and Toxicology, 117( 4), 234-241. doi:10.1111/bcpt.12400 -
NLM
Cau SBA, Guimarães DA, Rizzi E, Ceron CS, Gerlach RF, Tanus-Santos JE. The nuclear factor kappaB inhibitor pyrrolidine dithiocarbamate prevents cardiac remodelling and matrix metalloproteinase-2 up-regulation in renovascular hypertension [Internet]. Basic and Clinical Pharmacology and Toxicology. 2015 ; 117( 4): 234-241.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1111/bcpt.12400 -
Vancouver
Cau SBA, Guimarães DA, Rizzi E, Ceron CS, Gerlach RF, Tanus-Santos JE. The nuclear factor kappaB inhibitor pyrrolidine dithiocarbamate prevents cardiac remodelling and matrix metalloproteinase-2 up-regulation in renovascular hypertension [Internet]. Basic and Clinical Pharmacology and Toxicology. 2015 ; 117( 4): 234-241.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1111/bcpt.12400 - Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension
- Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension
- Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress
- Chronic treatment with nebivolol attenuates the vascular changes in the 2-kidney, 1-clip model of renovascular hypertension
- Circulating matrix metalloproteinases and their inhibitors in hypertension
- Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism
- Inibição de metaloproteinases (MMPs) com Doxycycline atenua a embolia pulmonar aguda (EPA)-indutor de hipotensão sistêmica
- Nicotine accutely increases plasma MMP-9 activity
- Atorvastatin and sildenafil reduce vascular remodeling and oxidative stress in 2K1C-hypertension
- Antioxidant treatment protects against matrix metalloproteinases activation and cardiomyocyte injury during acute pulmonary thromboembolism
Informações sobre o DOI: 10.1111/bcpt.12400 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
